ON-DEMAND WEBINARS

CGT pioneers require supply chain partnerships that mitigate trial risk and complexity. Explore how to optimize pre-trial and pre-screening activities and reduce trial cost and risk with an IRT solution.

See how AI-generated synthetic patient populations can mirror real trial outcomes, enabling teams to test assumptions, refine protocols, and anticipate variability early — helping reduce risk, cost, and time while improving study design decisions.

Willie Muehlhausen, Co-CEO and Founder of Safira Clinical Research, and Tim Davis, VP of Strategy at MyVeeva for Patients, discuss how ePRO delivery needs to change to better serve modern trials.

Join IRT industry veteran and drug supply expert Stefan Dürr for a discussion about how to reduce the impact of both traditional and emerging macroeconomic pressures on clinical trial supply.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

John Oncea Editor